A biomimetic nanoplatform for targeted co-delivery of ABT-199 and ATRA potentiates acute myeloid leukemia therapy via DNA damage response suppression.
Despite its clinical utility, the therapeutic potential of Venetoclax (ABT-199) in acute myeloid leukemia (AML) remains limited by the heterogeneous nature of the disease, which often leads to reduced efficacy of monotherapy. Herein, we demonstrate that ABT-199-induced apoptosis can be potentiated by all-trans retinoic...